Clinicopathological profile and outcomes of anorectal melanoma from a tertiary care center in India

• Published in: Future science OA Vol. 8; no. 4; p. FSO786
• Main Authors: Garg, Vikas, Rastogi, Sameer, Aswar, Harshal, Shamim, Shamim A, Dhamija, Ekta, Barwad, Adarsh, Pandey, Rambha, Panwar, Rajesh, Upadhyay, Ashish
• Format: Journal Article
• Language: English
• Published: England Future Science Ltd 01-04-2022; Taylor & Francis Group
• Subjects: anal; anorectal; chemotherapy; immunotherapy; melanoma; mucosal; rectal; Short Communication; anal; immunotherapy; anorectal; melanoma; rectal; chemotherapy; mucosal
• ISSN: 2056-5623; 2056-5623
• DOI: 10.2144/fsoa-2021-0091

Anorectal melanoma (AM) is a rare subtype of melanoma.
To study the clinic–pathologic features and outcomes in patients with AM.
Clinical, pathologic findings and outcomes of patients with AM were recorded.
Twenty-seven patients with AM were identified with median age of 57 years. Most patients presented in stage III (44.4%). Lymph node involvement was seen in 70.4%. The response to chemotherapy and immunotherapy was 16.6 and 25.0%, respectively. At a median follow up of 11 months, median overall survival was 30 months. Ballantine stage 3 and weight loss at presentation were predictors of poor survival.
AM presents at an advanced stage with lymph node and distant metastasis.
Anorectal melanoma is a rare subset of melanoma presenting at an advanced stage with lymph node and distant metastasis. Early disease is managed surgically; however, optimal treatment of advanced disease is unclear. The stage at diagnosis is the most important prognostic factor. Prognosis is poor, but with the advent of targeted therapy and immunotherapy, the outcomes are improving.